TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25632744
Drug: Zhibai Dihuang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhibai Dihuang Pill (ZBDHP), 6 g each time, twice daily for 90 days
Study: 22189364
Drug: Pneumatic pulsation
Normalized name: ABG Pulsator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumatic pulsation therapy (5 treatments over 2 weeks)
Study: 20003782
Drug: Low‐molecular‐weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐molecular‐weight heparin (LMWH)
Study: 15045190
Drug: Bazoton uno
Normalized name: unoprostone
DrugBank: Unoprostone (DB06826)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazoton uno (459 mg dry extract of stinging nettle roots)
Study: 11446046
Drug: Low-dose spiral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose spiral CT scanning
Study: 9543646
Drug: Nicotine (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (two 22 mg transdermal patches)
Study: 7515168
Drug: Interferons (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferons (in combination with chemotherapy and other immunological agents)
Study: 1984505
Drug: Glucose administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose administration
Study: 23514638
Drug: LIA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIA with ketorolac 30 mg
Study: 12201354
Drug: Delapril 30
Normalized name: Delapril
DrugBank: Delapril (DB13312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delapril 30 mg plus Indapamide 2.5 mg
Study: 7030636
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg slow-release metoprolol once daily for 6 weeks
Study: 7030636
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg conventional metoprolol once daily for 6 weeks
Study: 21838506
Drug: Levodopa therapy
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa therapy postoperatively
Study: 11996472
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg/m2 every 3 weeks)
Study: 9882028
Drug: Balsalazide 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balsalazide 3 g daily
Study: 23728065
Drug: Varenicline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (2 mg/d, titrated during the first week)
Study: 22215943
Drug: Peg‐α‐2b interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐α‐2b interferon (1.5 μg/kg per week) plus ribavirin (1000‐1200 mg/d) without vitamin D
Study: 11177331
Drug: Intravenous unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous unfractionated heparin
Study: 9477005
Drug: Flumazenil (benzodiazepine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (benzodiazepine antagonist)
Study: 25529979
Drug: LX4211 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LX4211 (400 mg for 7 days)
Study: 18401199
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections with indwelling catheter (Group A)
Study: 18401199
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections without indwelling catheter (Group B)
Study: 11495387
Drug: Nursing-led ward
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nursing-led ward care (treatment group)
Study: 7820976
Drug: Leucine infusion
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine infusion (1 g h‐1)
Study: 7820976
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion (20 g h‐1)
Study: 7820976
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of leucine and glucose infusions
Study: 30536154
Drug: ICH glasdegib
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICH glasdegib (100 mg) after high-fat, high-calorie meal
Study: 30536154
Drug: ICH glasdegib
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICH glasdegib (100 mg) with PPI (rabeprazole)
Study: 25295770
Drug: Activity prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity prescription intervention targeting sedentary intensity
Study: 25295770
Drug: Activity prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity prescription intervention targeting both exercise and sedentary intensity
Study: 15500257
Drug: Comfrey extract
Normalized name: comfrey leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comfrey extract ointment (Kytta-Salbe f, four treatments per day for 8 days)
Study: 8985298
Drug: Lamivudine 25
Normalized name: LAMIVUDINE 25MG/5ML SOLN,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 25 mg daily
Study: 7872992
Drug: Cimetidine treatment
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine treatment for one week
Study: 9555615
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for one week
Study: 15738010
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing of gentamicin (5.1 mg/kg every 24 hours; n = 18)
Study: 15738010
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing of gentamicin (120 mg followed by 80 mg every 8 hours; n = 20)
Study: 15738010
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing of gentamicin
Study: 15738010
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing of gentamicin
Study: 21752101
Drug: Methylprednisolone plus
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone plus Mycophenolate mofetil (3 g/day, 1.5 g twice daily)
Study: 15623591
Drug: Thalidomide 200
Normalized name: thalidomide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 200 mg daily
Study: 12519419
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (GH) treatment (0.04 U/kg/day for 14 weeks preoperatively and doubled for the first 2 weeks postoperatively)
Study: 3097099
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of recombinant tissue-type plasminogen activator (rt-PA)
Study: 29843467
Drug: New HM
Approvals — FDA: no, EMA: no, PMDA: no
Description: New HM fortifier (nHMF; n = 26) containing 12.5 g medium‐chain FA, 958 mg linoleic acid, 417 mg α‐linolenic acid, and 157 mg docosahexaenoic acid per 100 g of powder
Study: 8396087
Drug: Azithromycin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (n = 252) 500 mg once daily for three days
Study: 8396087
Drug: Clarithromycin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (n = 258) 250 mg twice daily for ten days
Study: 25596108
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy to the anorectum and rectum
Study: 15504839
Drug: SR clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SR clarithromycin (500 mg daily)
Study: 8116811
Drug: Halofantrine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine (3 doses of 500 mg each at 4-hr intervals on the first day, followed by 500 mg a day for six days; total dose 4.5 g)
Study: 20673731
Drug: Open reduction,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open reduction, rigid internal fixation, and functional treatment
Study: 17106197
Drug: Thalidomide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (100 mg once a day, increased to 100 mg twice a day after 10 days if tolerated)
Study: 14739814
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine analgesia
Study: 8112185
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg miglitol 3 times a day
Study: 8112185
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg miglitol 3 times a day
Study: 28808771
Drug: Classical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical treatment (antibiotics, anti-inflammatories and low-fibre diet)
Study: 28808771
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment (anti-inflammatories and low-fibre diet)
Study: 27656713
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg twice daily for four months
Study: 14767999
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care and hypertonic saline (30%) infusion to maintain serum sodium levels of 145‐155 mmol/L (Group 2)
Study: 9296466
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (dalteparin sodium, Fragmin)
Study: 8095362
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with haloperidol, chlorpromazine, and perphenazine
Study: 29764602
Drug: Minimally adequate
Normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally adequate treatment for psychiatric disorders
Study: 25675385
Drug: Saline (0.9%)
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (0.9%) infusion
Study: 25675385
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human TNF‐α (1000 ng/m(2) · h) infusion
Study: 10371400
Drug: Ethanol 0.8
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.8 g/kg
Study: 6125195
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg metoprolol
Study: 25917008
Drug: Exposure Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure Therapy (ET)
Study: 15781541
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL saline (placebo)
Study: 12559267
Drug: 11 mL
Normalized name: camphor 0.11 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11 mL of 0.2% oxybuprocaine hydrochloride gel
Study: 10342416
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three opioids (morphine, pethidine, fentanyl)
Study: 2681675
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine gluconate mouthrinse (CHx) used twice daily for 6 weeks
Study: 30952941
Drug: standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard treatment
Study: 12675873
Drug: Risk factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk factors (urinary protein ≥3 g/day and systolic blood pressure ≥140 mm Hg)
Study: 11140330
Drug: Low-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose interferon alpha (IFN-alpha) treatment
Study: 8243376
Drug: Felbamate (FBM)
Normalized name: Felbamate
DrugBank: Felbamate (DB00949)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felbamate (FBM) as monotherapy
Study: 8243376
Drug: Felbamate (FBM)
Normalized name: Felbamate
DrugBank: Felbamate (DB00949)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felbamate (FBM) as add-on therapy
Study: 2869850
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of catecholamines with alpha 2 agonist activity (60-120 min)
Study: 27741949
Drug: Hydrocortisone 50
Normalized name: hydrocortisone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 50 mg every 6 hours
Study: 25335327
Drug: Mecobalamine Tablet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecobalamine Tablet, 500 microg each time, 3 times per day
Study: 12356155
Drug: Combined electrocautery
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined electrocautery pencil and suction with intravenous infusion catheter
Study: 10358229
Drug: Alcoholic solution
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcoholic solution
Study: 7049308
Drug: Preoperative intraparietal
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative intraparietal (intra-incisional) injection of cefoxitin
Study: 26783095
Drug: Ranibizumab monthly
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab monthly
Study: 17902186
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg Ginkgo biloba extract (GBE)
Study: 15139796
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 6.9 mg [14C]ciclesonide
Study: 15139796
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 0.64 mg [14C]ciclesonide
Study: 9747866
Drug: CAF (cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF (cyclophosphamide, doxorubicin, and 5-flurouracil) dose-intensive treatment
Study: 29161199
Drug: Budesonide nasal
Normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide nasal spray
Study: 31006955
Drug: Lidocaine-Propitocain Cream
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine-Propitocain Cream (EMLA)
Study: 16616164
Drug: manualized 24-session
Approvals — FDA: no, EMA: no, PMDA: no
Description: manualized 24-session treatment incorporating motivational interviewing and emotion coping and communication skills
Study: 12865901
Drug: Pentagastrin (cholecystokinin-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentagastrin (cholecystokinin-B receptor agonist)
Study: 21684088
Drug: Multidimensional Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidimensional Family Therapy (MDFT)
Study: 24632279
Drug: Drug-eluting stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stent (DES) treatment in patients with DM and type A/B1 lesions
Study: 24632279
Drug: Drug-eluting stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stent (DES) treatment in patients without DM and type A/B1 lesions
Study: 19101456
Drug: HPV‐16/18 AS04‐adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV‐16/18 AS04‐adjuvanted vaccine
Study: 17655704
Drug: Simvastatin administered
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin administered during two cycles of treatment
Study: 15228063
Drug: Jellyfish sting
Normalized name: zinc acetate 0.001 mg in 1 mL TOPICAL POWDER, FOR SUSPENSION [Advanced Jellyfish Sting Kit]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jellyfish sting inhibitor (Nidaria Technology Ltd, Jordan Valley, Israel)
Study: 7644244
Drug: H-wave therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-wave therapy (HWT) at various frequencies (2-60 Hz)
Study: 752864
Drug: Weekly applications
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly applications of BCG
Study: 15305182
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (Control)
Study: 16115341
Drug: Daily antioxidant
Normalized name: Ascorbic Acid/Selenium/Vitamin A/Vitamin E Oral Capsule, Liquid Filled [DAILY ANTIOXIDANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily antioxidant supplementation (120 mg vitamin C, 30 mg vitamin E, 6 mg beta-carotene, 100 microg Se, 20 mg Zn)
Study: 16115341
Drug: Daily antioxidant
Normalized name: Ascorbic Acid/Selenium/Vitamin A/Vitamin E Oral Capsule, Liquid Filled [DAILY ANTIOXIDANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily antioxidant supplementation
Study: 28017166
Drug: Transforaminal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal epidural steroid injections
Study: 11805628
Drug: Saline trigger-point
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline trigger-point injections
Study: 8815273
Drug: Benazepril (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (10-20 mg once daily)
Study: 8815273
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg 1-2 times daily)
Study: 6993706
Drug: Single 3-g
Normalized name: glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 3-g oral dose of amoxicillin trihydrate
Study: 6993706
Drug: Conventional ten-day
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ten-day courses of oral ampicillin sodium
Study: 11044538
Drug: Combination pill
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination pill
Study: 27649778
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg caffeine
Study: 17972452
Drug: Autologous platelet
Normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet gel (APG) and activated platelet-poor plasma (PPP) treatment
Study: 9562353
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion at 40 mU x m(‐2) x min(‐1) with 20% glucose to maintain euglycaemia
Study: 14995946
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl infusion (control)
Study: 2509305
Drug: Estrogen cream
Normalized name: ESTRIOL 4 mg in 85 g / ESTRADIOL 1 mg in 85 g TRANSDERMAL CREAM [BiEST 5.0 Estrogen Cream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen cream (B)
Study: 183788
Drug: LF 178
Normalized name: HYDROXYPROPYL CELLULOSE LF
Approvals — FDA: no, EMA: no, PMDA: no
Description: LF 178 (200 to 400 mg daily for 1 to 18 months)
Study: 25440329
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg (group B)
Study: 25440329
Drug: No atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No atorvastatin (group C)
Study: 17039216
Drug: Back School
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Back School treatment
Study: 11529534
Drug: Intranasal sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal sedation with midazolam
Study: 9101306
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (nifedipine or nicardipine)
Study: 12805339
Drug: RSR13 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSR13 plus cranial radiation therapy (30 Gy in 10 fractions of 3 Gy each).
Study: 12409685
Drug: Antidepressants (imipramine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (imipramine, phenelzine, L-deprenyl, mianserin, desipramine)
Study: 7921519
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nicorandil
Study: 2945420
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nicorandil
Study: 2534416
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nicorandil
Study: 3048155
Drug: Ticlopidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (250 mg, twice daily)
Study: 26083656
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose
Study: 26614143
Drug: Injection lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection lignocaine 0.2 mg/kg
Study: 3560070
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg metergoline
Study: 3560070
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg bromoergocriptine
Study: 30407744
Drug: Needle injection
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle injection
Study: 28651515
Drug: Adjunctive corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive corticosteroid treatment
Study: 24298765
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at Jing-well points on the differentiated meridians and temple-three-needle therapy
Study: 12953031
Drug: On-line convective
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-line convective treatments (HF and HDF)
Study: 23065392
Drug: Crude methanolic
Normalized name: methanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crude methanolic extracts of Euphorbia helioscopia at concentrations of 12.5 mg/ml, 25 mg/ml, and 50 mg/ml
Study: 23065392
Drug: Methanolic and
Normalized name: methanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methanolic and aqueous extracts of Euphorbia helioscopia at concentrations ranging from 100 to 500 mg/ml
Study: 20848384
Drug: Illustration group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Illustration group (detailed illustrations regarding medication use)
Study: 20848384
Drug: Oral group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral group (standard oral postoperative instructions)
Study: 11322350
Drug: Tolterodine, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine, 2 mg twice daily
Study: 15478523
Drug: Tolterodine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine at self-selected doses (SSDs)
Study: 15478523
Drug: Oxybutynin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin at self-selected doses (SSDs)
Study: 7882730
Drug: RYHB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RYHB vaccine (20 micrograms per dose)